Phase i dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma

Leukemia and Lymphoma

Volumn 56, Issue 10, 2015, Pages 2834-2840

  Awan, Farrukh T ^a   Flynn, Joseph M ^a   Jones, Jeffrey A ^a   Andritsos, Leslie A ^a   Maddocks, Kami J ^a   Sass, Ellen J ^a   Lucas, Margaret S ^a   Chase, Weihong ^a   Waymer, Sharon ^a   Ling, Yonghua ^a   Jiang, Yao ^a   Phelps, Mitch A ^a   Byrd, John C ^a   Lucas, David M ^a   Woyach, Jennifer A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

carfilzomib; chronic lymphocytic leukemia; Proteasome inhibitor

Indexed keywords

CARFILZOMIB; DEXAMETHASONE; FLUDARABINE; HEMOGLOBIN; IBRUTINIB; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN HEAVY CHAIN; OLIGOPEPTIDE; PROTEASOME INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HUMAN; HYPERKALEMIA; HYPERNATREMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INTERPHASE; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LYMPHOCYTOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PREMEDICATION; PRIORITY JOURNAL; SIDE EFFECT; SINUS TACHYCARDIA; SMALL LYMPHOCYTIC LYMPHOMA; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRISOMY 12; VOLUME OF DISTRIBUTION; CHROMOSOME ABERRATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; OLIGOPEPTIDES; PROTEASOME INHIBITORS; TREATMENT OUTCOME;

EID: 84947560068     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1014368     Document Type: Article

References (33)

1. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15:48-58.
2. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
3. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371:213-223.
4. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370: 997-1007.
5. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390-3397.
6. Crawford LJ, Irvine AE. Targeting the ubiquitin proteasome system in haematological malignancies. Blood Rev 2013;27:297-304.
7. Iglesias-Serret D, de Frias M, Santidrian AF, et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2007;21:281-287.
8. Fuchs SY. The role of ubiquitin-proteasome pathway in oncogenic signaling. Cancer Biol Ther 2002;1:337-341.
9. Kabore AF, Sun J, Hu X, et al. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006;11:1175-1193.
10. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
11. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-4874.
12. Kelley TW, Alkan S, Srkalovic G, et al. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res 2004;28:845-850.
13. Duechler M, Linke A, Cebula B, et al. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol 2005;74:407-417.
14. Pahler JC, Ruiz S, Niemer I, et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 2003;9:4570-4577.
15. Faderl S, Rai K, Gribben J, et al. Phase II study of singleagent bortezomib for the treatment of patients with fludarabinerefractory B-cell chronic lymphocytic leukemia. Cancer 2006;107: 916-924.
16. Liu FT, Agrawal SG, Movasaghi Z, et al. Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 2008;112:3835-3846.
17. Zhou HJ, Aujay MA, Bennett MK, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009;52:3028-3038.
18. Kim KB, Crews CM. From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. Nat Prod Rep 2013;30:600-604.
19. Kortuem KM, Stewart AK. Carfilzomib. Blood 2013;121:893-897.
20. Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999;96:10403-10408.
21. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-6391.
22. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-3290.
23. Meiners S, Heyken D, Weller A, et al. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes. J Biol Chem 2003; 278:21517-21525.
24. Gupta SV, Hertlein E, Lu Y, et al. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-kappaB response in chronic lymphocytic leukemia cells. Clin Cancer Res 2013;19:2406-2419.
25. Hertlein E, Byrd JC. Signalling to drug resistance in CLL. Best Pract Res Clin Haematol 2010;23:121-131.
26. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
27. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286-2294.
28. Wickremasinghe RG. Why is CLL refractory to bortezomib? Blood 2008;112:3540-3541.
29. Chen D, Daniel KG, Chen MS, et al. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 2005;69:1421-1432.
30. O'Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15:7085-7091.
31. Papadopoulos KP, Burris HA 3rd, Gordon M, et al. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013;72:861-868.
32. Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos 2013;41:230-237.
33. Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012;18:4830-4840.